Drug Search Results

Varespladib

Alternative Names: varespladib
Latest Update: 2024-10-23
Latest Update Note: News Article

Product Description

Mechanisms of Action: PLA2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Anthera
Company Location: HAYWARD CA 94545
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Varespladib

Countries in Clinic: India, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Snake Bites

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
BRAVIO	P2	Recruiting	Snake Bites	2025-03-01
BRAVO	P2	Completed	Snake Bites	2023-06-07	24%

Recent News Events

Date	Type	Title
10/23/2024	News Article	Ophirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims
07/15/2024	News Article	Ophirex Appoints Jeremy Gowler as Chief Executive Officer
05/07/2024	PubMed	Dermonecrosis caused by a spitting cobra snakebite results from toxin potentiation and is prevented by the repurposed drug varespladib.
05/06/2024	PubMed	Varespladib mitigates acute liver injury via suppression of excessive mitophagy on Naja atra envenomed mice by inhibiting PLA(2).
04/07/2024	PubMed	Development of a membrane-disruption assay using phospholipid vesicles as a proxy for the detection of cellular membrane degradation.
01/05/2023	News Article	Ophirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment
03/02/2020	News Article	Ophirex Receives Wellcome Trust Award to Advance Clinical Development of Novel Snakebite Treatment

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions